Aberdeen, Scotland and Singapore, Singapore--(Newsfile Corp. - January 11, 2021) - TauRx Pharmaceuticals Ltd today announced it has completed patient enrolment of the LUCIDITY study (NCT03446001) ahead of schedule, despite delays due to the COVID-19 pandemic.
Aberdeen, Scotland and Singapore, Singapore--(Newsfile Corp. - January 11, 2021) - TauRx Pharmaceuticals Ltd today announced it has completed patient enrolment of the LUCIDITY study (NCT03446001) ahead of schedule, despite delays due to the COVID-19 pandemic. TauRx is pleased to be presenting its latest trial results at Biotech Showcase 2021 during the J.P. Morgan 39th Annual Healthcare Conference 2021. LUCIDITY is the only late-stage study targeting the tau pathology of Alzheimer’s disease. It aims to confirm hydromethylthionine as the first tau-based disease modifying treatment for Mild Cognitive Impairment and Mild-Moderate AD.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- TauRx Pharmaceuticals Ltd today announced it has completed patient enrolment of the LUCIDITY study (NCT03446001) ahead of schedule, despite delays due to the COVID-19 pandemic.
- TauRx is pleased to be presenting its latest trial results at Biotech Showcase 2021 during the J.P. Morgan 39th Annual Healthcare Conference 2021.
- If the efficacy of hydromethylthionine is confirmed, it will open up a completely new treatment direction for a devastating disease which has so far defied all efforts to bring it under control.
Click image above to view full announcement.
Contacts:
TauRx Media
r.andersen@taurx.com
Source: TauRx
